F I Araujo1, F P P Proença2, C G Ferreira3, S C Ventilari4, P H Rosado de Castro2, R D Moreira3, L M B Fonseca1, S A L Souza1, B Gutfilen1. 1. 1 Departamento de Radiologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 2. 2 Nuclear Medicine Section, National Cancer Institute, Rio de Janeiro, Brazil. 3. 3 Coordination of Clinical Research, National Cancer Institute, Rio de Janeiro, Brazil. 4. 4 Division of Clinical Oncology, National Cancer Institute, Rio de Janeiro, Brazil.
Abstract
OBJECTIVE: Doxorubicin (Eurofarma, São Paulo, Brazil) is an antitumour agent widely used in the treatment of breast cancer and can be used for tumour tracking when labelled with a radionuclide. Here, we present the results obtained with technetium-99m ((99m)Tc)-doxorubicin, using the direct method, to evaluate its uptake in breast cancer. METHODS: Four females with confirmed breast carcinoma diagnosis and breast image reporting and data system Category 5 on mammography underwent whole-body and thorax single-photon emission CT/CT imaging 1 and 3 h after (99m)Tc-doxorubicin administration. RESULTS: We observed increased uptake in breast carcinoma lesions and elimination via renal and hepatic pathways. CONCLUSION: These preliminary results suggest that (99m)Tc-doxorubicin may be a promising radiopharmaceutical for the evaluation of patients with breast cancer. Further studies are ongoing. ADVANCES IN KNOWLEDGE: To our knowledge, this is the first study to evaluate the use of a directly labelled doxorubicin tracer in humans. (99m)Tc-doxorubicin could provide information on the response of tumours to doxorubicin.
OBJECTIVE:Doxorubicin (Eurofarma, São Paulo, Brazil) is an antitumour agent widely used in the treatment of breast cancer and can be used for tumour tracking when labelled with a radionuclide. Here, we present the results obtained with technetium-99m ((99m)Tc)-doxorubicin, using the direct method, to evaluate its uptake in breast cancer. METHODS: Four females with confirmed breast carcinoma diagnosis and breast image reporting and data system Category 5 on mammography underwent whole-body and thorax single-photon emission CT/CT imaging 1 and 3 h after (99m)Tc-doxorubicin administration. RESULTS: We observed increased uptake in breast carcinoma lesions and elimination via renal and hepatic pathways. CONCLUSION: These preliminary results suggest that (99m)Tc-doxorubicin may be a promising radiopharmaceutical for the evaluation of patients with breast cancer. Further studies are ongoing. ADVANCES IN KNOWLEDGE: To our knowledge, this is the first study to evaluate the use of a directly labelled doxorubicin tracer in humans. (99m)Tc-doxorubicin could provide information on the response of tumours to doxorubicin.
Authors: Anuradha Soundararajan; Ande Bao; William T Phillips; Linda M McManus; Beth A Goins Journal: Cancer Biother Radiopharm Date: 2011-08-11 Impact factor: 3.099
Authors: Lea Mirian Barbosa da Fonseca; Valeria Battistella; Gabriel Rodriguez de Freitas; Bianca Gutfilen; Regina Coeli Dos Santos Goldenberg; Angelo Maiolino; Eduardo Wajnberg; Paulo Henrique Rosado de Castro; Rosalia Mendez-Otero; Charles Andre Journal: Circulation Date: 2009-08-11 Impact factor: 29.690
Authors: Lea Mirian Barbosa da Fonseca; Bianca Gutfilen; Paulo Henrique Rosado de Castro; Valeria Battistella; Regina C S Goldenberg; Tais Kasai-Brunswick; Claudia L R Chagas; Eduardo Wajnberg; Angelo Maiolino; Sérgio Salles Xavier; Charles Andre; Rosalia Mendez-Otero; Gabriel R de Freitas Journal: Exp Neurol Date: 2009-10-22 Impact factor: 5.330
Authors: Michael K O'Connor; Stephen W Phillips; Carrie B Hruska; Deborah J Rhodes; Douglas A Collins Journal: Breast J Date: 2007 Jan-Feb Impact factor: 2.431
Authors: Deborah J Rhodes; Michael K O'Connor; Stephen W Phillips; Robin L Smith; Douglas A Collins Journal: Mayo Clin Proc Date: 2005-01 Impact factor: 7.616
Authors: Jean-Louis Alberini; Florence Lerebours; Myriam Wartski; Emmanuelle Fourme; Elise Le Stanc; E Gontier; O Madar; P Cherel; A P Pecking Journal: Cancer Date: 2009-11-01 Impact factor: 6.860
Authors: A Gil-Rendo; F Martínez-Regueira; G Zornoza; M J García-Velloso; C Beorlegui; N Rodriguez-Spiteri Journal: Br J Surg Date: 2009-02 Impact factor: 6.939
Authors: Juliana O Silva; Renata S Fernandes; Sávia C A Lopes; Valbert N Cardoso; Elaine A Leite; Geovanni D Cassali; Maria Cristina Marzola; Domenico Rubello; Monica C Oliveira; Andre Luis Branco de Barros Journal: Mol Imaging Biol Date: 2016-12 Impact factor: 3.488